The accompanying table [click to enlarge] presents statistics and the top 15 rated companies in the ETF Innovators [ETFI] Preventive Medicine Index. The index includes U.S.-listed companies with market caps of $200M-$60B which are engaged in the following healthcare business segments: vaccine makers, diagnostics, lab services, and diabetes care.
The index has outpaced the overall market, Healthcare Sector SPDR (XLV), HealthShares Diagnostics (HHD), and iShares Nasdaq Biotech (IBB) over the past year, posting a slight gain of 0.8% for the top 30 rated companies despite double digit losses for the overall market and benchmark healthcare ETFs.
With the announcement that HealthShares will close its remaining four funds by year-end, the ETFI Preventive Medicine Index represents a new ETF idea which expands upon their most popular product by net assets, HealthShares Diagnostics (HHD), with the inclusion of vaccine makers such as Emergent BioSolutions (EBS), diabetes care companies such as Novo Nordisk (NVO), and diagnostic companies not included in HHD such as Sequenom (SQNM), China Medical (CMED), Genoptix (GXDX), and Genomic Health (GHDX).
$17.13 (12/04/08)
